末期腎病 (ESRD) 市場規模、佔有率、成長分析、按治療、按診斷、按最終用途、按地區 - 行業預測，2025-2032 年

2023年全球末期腎病（ESRD）市場規模為1120.8億美元，在預測期內從2024年的1267.6億美元成長到2032年的3393.8億美元（預計複合年成長率為13.1） 2025 年至2032 年的百分比）。

由於慢性腎臟病（CKD）盛行率的上升和醫療技術的進步，特別是低維護透析系統和人工腎臟的進步，腎衰竭市場正在經歷顯著成長。 CKD 是由糖尿病、高血壓和生活習慣引起的，影響著世界上約 10% 的人口。中國和印度等開發中國家的老年人口尤其脆弱，末期腎病 (ESRD) 病例每年增加 5-7%。美國約有 8,000 萬成年人面臨 CKD 的風險，而 CKD 已被證明是導致死亡的主要原因。穿戴式人工腎臟 2.0 等創新和強大的醫療基礎設施正在促進市場擴張。目前約 7,500 家透析診所網路的擴張進一步支持了這一趨勢。

目錄

介紹

• 研究目的
• 調查範圍
• 定義

調查方法

• 資訊採購
• 二手資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 抑制因素和挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 價格分析
• 產品平臺分析
• 案例研究分析
• 專利分析
• 監管分析

按治療分類的末期腎病 (ESRD) 市場規模

• 市場概況
• 移植
• 透析
  • 腹膜透析
  • 血液透析機
  • 穿戴式人工腎

按診斷分類的末期腎病 (ESRD) 市場規模

• 市場概況
• 驗血
• 尿液檢查
• 影像檢查
• 其他

以最終用途分類的末期腎病 (ESRD) 市場規模

• 市場概況
• 醫院
• 透析中心
• 其他

末期腎病（ESRD）市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東/非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲

競爭資訊

• 前5名企業對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分類的佔有率分析
  • 收益與前一年同期比較（2022-2024）

主要企業簡介

• AngioDynamics, Inc.（US）
• Asahi Kasei Medical Co., Ltd.（Japan）
• B. Braun Melsungen AG（Germany）
• Baxter International, Inc.（US）
• Becton Dickinson and Company（US）
• Cantel Medical（US）
• DaVita Inc.（US）
• Fresenius Medical Care AG & Co. KGaA（Germany）
• JMS Co., Ltd.（Japan）
• Medtronic Plc（Ireland）
• Nikkiso Co., Ltd.（Japan）
• Nipro Corporation（Japan）
• Teleflex Incorporated（US）
• Toray Industries Inc.（Japan）
• US Renal Care, Inc.（US）
• Pfizer Inc.（US）
• AstraZeneca（UK）
• Bristol-Myers Squibb Company（US）
• Dr. Reddy's Laboratories Ltd.（India）
• Endo International plc（Ireland）

結論和建議

Global End-Stage Renal Disease (ESRD) Market size was valued at USD 112.08 billion in 2023 and is poised to grow from USD 126.76 billion in 2024 to USD 339.38 billion by 2032, growing at a CAGR of 13.1% during the forecast period (2025-2032).

The kidney failure market is experiencing significant growth, driven by the rising incidence of Chronic Kidney Disease (CKD) and advancements in medical technology, particularly low-maintenance dialysis systems and artificial kidneys. CKD, stemming from diabetes, hypertension, and lifestyle factors, affects roughly 10% of the global population. The elderly demographic in developing nations like China and India is particularly vulnerable, with cases of end-stage renal disease (ESRD) increasing annually by 5-7%. In the U.S., approximately 80 million adults are at risk for CKD, underscoring its status as a leading cause of mortality. Market expansion is fueled by innovations such as the Wearable Artificial Kidney 2.0 and a robust healthcare infrastructure. The growing network of dialysis clinics, now numbering around 7,500, further supports this upward trajectory.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global End-Stage Renal Disease (Esrd) market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global End-Stage Renal Disease (Esrd) Market Segmental Analysis

Global End-Stage Renal Disease (ESRD) Market is segmented by treatment, diagnosis, end use and region. Based on treatment, the market is segmented into transplant and dialysis. Based on diagnosis, the market is segmented into blood test, urine test, imaging test and others. Based on end use, the market is segmented into hospitals, dialysis centers and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global End-Stage Renal Disease (Esrd) Market

One of the primary factors driving the global end-stage renal disease (ESRD) market is the rising incidence of chronic kidney disease (CKD), which is often linked to prevalent conditions like hypertension and diabetes. As these chronic ailments become increasingly common, a larger segment of the population is at risk of developing CKD, which can ultimately lead to ESRD. This growing patient demographic heightens the need for effective treatment modalities such as dialysis and kidney transplantation. Consequently, this heightened demand for specialized care and interventions is significantly contributing to the expansion and growth of the ESRD market on a global scale.

Restraints in the Global End-Stage Renal Disease (Esrd) Market

One significant challenge in the global End-Stage Renal Disease (ESRD) market is the restricted availability and accessibility of treatment options, particularly kidney transplantation. The demand for kidney transplants vastly overshadows the supply of compatible organs, resulting in extensive waiting lists and prolonged delays for patients in need. Furthermore, while dialysis serves as a viable treatment, it comes with its own set of obstacles, including issues related to patient adherence, high costs, and the requirement for frequent treatment sessions. These factors collectively hinder timely access to optimal care for individuals suffering from end-stage renal disease, ultimately affecting the growth of the market.

Market Trends of the Global End-Stage Renal Disease (Esrd) Market

A prominent market trend in the global end-stage renal disease (ESRD) sector is the rising prevalence of home-based dialysis treatments, which cater to patients' demands for convenience, reduced healthcare costs, and improved health outcomes. Growing preferences for modalities like peritoneal dialysis and home hemodialysis reflect a desire for increased flexibility and independence, allowing patients to undergo treatment in a familiar environment. This shift is further fueled by technological advancements, robust training initiatives, and supportive reimbursement frameworks, all of which facilitate the transition to home dialysis. Consequently, this trend is significantly propelling the growth and transformation of the ESRD market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Product Pipeline Analysis
• Case Study Analysis
• Patent Analysis
• Regulatory Analysis

Global End-Stage Renal Disease (ESRD) Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Transplant
• Dialysis
  • Peritoneal Dialysis
  • Hemodialysis
  • Wearable Artificial Kidney

Global End-Stage Renal Disease (ESRD) Market Size by Diagnosis & CAGR (2025-2032)

• Market Overview
• Blood Test
• Urine Test
• Imaging Test
• Others

Global End-Stage Renal Disease (ESRD) Market Size by End Use & CAGR (2025-2032)

• Market Overview
• Hospitals
• Dialysis Centers
• Others

Global End-Stage Renal Disease (ESRD) Market Size & CAGR (2025-2032)

• North America (Treatment, Diagnosis, End Use)
  • US
  • Canada
• Europe (Treatment, Diagnosis, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment, Diagnosis, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment, Diagnosis, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment, Diagnosis, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AngioDynamics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Asahi Kasei Medical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• B. Braun Melsungen AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton Dickinson and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cantel Medical (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DaVita Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Medical Care AG & Co. KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• JMS Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic Plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nikkiso Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nipro Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teleflex Incorporated (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Toray Industries Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• U.S. Renal Care, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Endo International plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations